NUMA1 and breast carcinoma: In vivo mouse breast cancer and lung metastatic models were generated to evaluate the combination treatment of SMI-4a and Lys-o5 inhibitors.<h4>Results</h4>We identified that high expression of NuMA1 associated with poor survival of breast cancer patients.